-
A study comparing experienced meditators and non-meditators found that the meditators had more favorable changes in some biochemical markers of stress-linked cell damage and inflammation. Those in both groups who responded more effectively to a stressful stimulus also showed somewhat better marker levels than those who responded less well.
-
In a systematic review and meta-analysis of prospective studies examining the association between mental stress-induced myocardial ischemia (MSIMI) and adverse outcome events in patients with stable CAD, all existing investigations point to an approximate doubling of cardiovascular risk in patients with MSIMI.
-
-
The first in a new class of orexin receptor antagonists has been approved by the FDA for the treatment of insomnia. Orexins are hypothalamic neuropeptides that appear to have a role in maintaining wakefulness.
-
The American College of Physicians recommends against performing screening pelvic examination in asymptomatic, nonpregnant, adult women.
-
-
Detecting HIV early creates opportunity for treatment and reduces transmission risk.
-
Doran B, et al. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: Insight from the National Health and Nutrition Examination Survey III
-
Migraine is associated with multiple disorders, including irritable bowel syndrome, restless legs syndrome, and non-alcoholic fatty liver disease. Understanding how these disparate disorders link to migraine may lead to an increased understanding of the pathogenesis of this complex neurological condition.
-
The FDA has approved a mu-opioid receptor antagonist for the treatment of opioid-induced constipation (OIC). Naloxegol is a pegylated derivative of naloxone which acts on peripheral (e.g., gut) mu-receptors. It is marketed by AstraZeneca Pharmaceuticals as Movantik.
